Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 164 points (-1.0%) at 16,209 as of Thursday, Jan. 23, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 966 issues advancing vs. 2,022 declining with 119 unchanged. The Health Services industry currently sits down 0.7% versus the S&P 500, which is down 0.9%. On the negative front, top decliners within the industry include Mindray Medical International Limited ADR r ( MR), down 4.4%, Agilent Technologies ( A), down 2.0%, DaVita HealthCare Partners ( DVA), down 1.4%, Thermo Fisher Scientific ( TMO), down 1.4% and Boston Scientific ( BSX), down 1.2%. A company within the industry that increased today was Smith & Nephew ( SNN), up 0.7%. TheStreet would like to highlight 4 stocks pushing the industry lower today: 4. Becton Dickinson ( BDX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Becton Dickinson is down $0.88 (-0.8%) to $110.68 on light volume. Thus far, 256,824 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 750,200 shares. The stock has ranged in price between $110.32-$111.39 after having opened the day at $111.39 as compared to the previous trading day's close of $111.56. Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $21.6 billion and is part of the health care sector. The company has a P/E ratio of 23.9, above the S&P 500 P/E ratio of 17.7. Shares are up 1.0% year-to-date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Becton Dickinson a buy, 3 analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.